NCCN_Guidelines
NCCN指南：恶性胸膜间皮瘤(中文)
恶性胸膜间皮瘤
版本 1.2020—2019 年 11 月 27 日
NCCN 指南® 继续
本指南由授渔知识翻译，由于译者水平有限，难免会有错误或不恰当之处，翻译内容仅供谨慎参考。
NCCN Guidelines Version 1.2020 Malignant Pleural Mesothelioma
不能操作
PS 0–2
考虑
观察f 或化疗g
进展
PS 3–4
最佳支持治疗h
参见主要部 分 治疗 (MPM-3)
g
化疗
b 基于 CT 成像进一步评价可能的胸部、脊柱、膈肌或血管受累。 c 如果患者患有早期疾病，双相型组织学应考虑手术。 d 如果确定为 N2 疾病，则手术（和其他治疗）的预后显著降低。手术切除只能在临床试验环境下或在具有 MPM 专业知识的中心考虑。 e 如果要进行 PET/CT，建议在胸膜固定术前进行 PET/CT。胸膜固定术前确诊为 MPM。如果怀疑 MPM，考虑评估由具有 MPM 专业知识的多学科团队进行。 f 如果在出现症状性或放射学进展时计划进行化疗，则可考虑对无症状且疾病负荷极小的患者进行观察。 g 见全身治疗原则 (MPM-A). h 见支持治疗原则 (MPM-B).
诱导
化疗g 联合培美曲塞和顺 铂（或卡铂）
• 胸部增强 CT • PET/CT 用于
纵隔的 评估基于 CT 或其他 证据 晚期疾病
可切除 手术探查i
不可切除
胸膜切除术/去 皮质术i 或胸膜
观察结果或 RTk
外
i 半胸 RTk
肺切除术
化疗h
g
进展
手术探查i
可切除
NCCN小细胞肺癌临床实践指南2014.V1
Consensus: All recommendations are category 2A unless otherwise specified. See NCCN Categories of Evidence and Consensus.
NCCN Guidelines Version 1.2014 Panel Members Small Cell Lung Cancer
* Gregory P. Kalemkerian, MD/Chair † University of Michigan Comprehensive Cancer Center Wallace Akerley, MD † Huntsman Cancer Institute at the University of Utah
®
NCCN Guidelines Index SCLC Table of Contents Discussion
Clinical Trials: NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged. To find clinical trials online at NCCN Member Institutions, click here: /clinical_trials/physician.html.
Continue
Version 1.2014 05/28/13 © National Comprehensive Cancer Network, Inc. 2013, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®.
NCCN肿瘤学临床实践指南(《NCCN指南》)
Adetola Kassim医学博士和理科硕士 ‡ ξ Vanderbilt-Ingram Cancer Center
Amrita Y. Krishnan医学博士 ‡ City of Hope Comprehensive Cancer Center
* William Bensinger医学博士/副主席† ξ
Fred Hutchinson Cancer Research Center/ Seattle Cancer Care Alliance
Melissa Alsina医学博士 ‡ Moffitt Cancer Center
Djordje Atanackovic医学博士 Huntsman Cancer Institute at the University of Utah
2015年第2版，2014年9月30日。©美国国家综合癌症网络公司（NCCN）。2014年，保留所有权利。未经NCCN®明确书面授权不许以任何形式转载《NCCN指南》(NCCN Guidelines®)及本插图。
Noopur Raje医学博士 † ‡ Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center
ቤተ መጻሕፍቲ ባይዱ
Printed by Maria Chen on 1/22/2015 1:53:14 AM. For personal use only. Not approved for distribution. Copyright © 2015 National Comprehensive Cancer Network, Inc., All Rights Reserved.
nccn乳腺癌中文版指南乳腺癌指南
临床研究
中国乳腺癌的临床研究逐渐增多，涉及早期诊断、新辅助治疗、辅 助治疗等方面，为患者提供了更多的治疗选择和希望。
05
CATALOGUE
nccn乳腺癌指南在中国的应用和实施
nccn乳腺癌指南在中国的推广和应用
乳腺癌是中国女性最常见的恶性肿瘤 之一，nccn乳腺癌指南的推广和应用 对于提高乳腺癌的诊断和治疗水平具 有重要意义。
肿瘤生长。
放疗
对于某些特定情况，如 保乳手术后，需要进行 放疗以降低复发风险。
靶向治疗
针对特定基因突变或受 体，采用靶向药物进行 治疗，以提高疗效和降
低副作用。
乳腺癌的随访和监测
随访频率
建议术后定期随访，一般前2年 每3-6个月一次，之后每年一次
。
随访内容
包括体检、乳腺X线检查、B超等 ，以及必要的实验室检查和影像
1 2 3
指导临床实践
nccn乳腺癌指南为临床医生提供了关于乳腺癌的 诊断、治疗和管理的详细指导，确保了治疗的标 准化和规范化。
提高诊疗水平
通过遵循nccn乳腺癌指南，医疗机构可以确保乳 腺癌患者得到最佳的诊疗服务，从而提高诊疗效 果和患者的生存率。
推动研究进展
nccn乳腺癌指南的更新和改进是基于最新的医学 研究和临床试验结果，因此它也推动了乳腺癌领 域的研究进展。
复发和转移风险高
中国乳腺癌患者的复发和转移风险较 高，需要更加关注患者的长期生存和 康复。
心理和社会支持不足
乳腺癌患者需要更多的心理和社会支 持，但目前这方面的服务相对较少。
中国乳腺癌的研究进展
基础研究进展
中国乳腺癌的基础研究取得了一定的进展，涉及基因突变、表观 遗传学、肿瘤微环境等方面。
nccn指南是什么意思
NCCN指南是什么意思
NCCN指南全称为National Comprehensive Cancer Network，是一个国际知名的癌症治疗指南组织。
NCCN成立于1995年，总部位于美国宾夕法尼亚州。
该组织由21个美国知名的癌症中心共同组成，旨在提供最新、最全面的癌症诊断和治疗指南，以帮助临床医生和患者做出科学、权威的治疗决策。
NCCN指南以专家共识为基础，更新周期较短，通常每年更新一次。
该指南覆盖了多种癌症类型，包括但不限于乳腺癌、肺癌、结直肠癌、前列腺癌等。
指南内容主要包括疾病诊断、分期、治疗方案、药物选择和副作用管理等方面。
在临床实践中，NCCN指南被广泛认可和采用。
医生可以根据患者的具体情况和病情，参考NCCN指南的建议，制定个性化的治疗方案。
患者和家属也可以通过查阅指南，了解最新的治疗进展、疗效和不良反应，有助于提高治疗的效果和质量。
总的来说，NCCN指南是一个权威且实用的癌症治疗指南，旨在为癌症患者提供最佳的治疗选择。
通过及时更新的临床实践指南，NCCN致力于改善癌症患者的生存质量和长期生存率，为医务人员提供科学的治疗方案，为癌症防治工作做出积极的贡献。
NCCN指南：肺癌筛查(中文)
NCCN Guidelines Index Table of Contents Discussion
概述
肺癌是美国和全球癌症相关死亡的主要原因。1-5 2019 年，估计美国将发 生 142,670 例肺癌死亡（男性 76,650 例，女性 66,020 例），约占美国 所有癌症死亡的 24%。肺癌的 5 年生存率仅为 19%，部分原因是大多数患 者在初次诊断时已是晚期肺癌。7 这些事实——加上筛查在改善宫颈癌、 结肠癌和乳腺癌患者结局方面的成功——一直是研究开发一种有效的肺癌 筛查检测方法的动力。8-10 理想情况下，有效的筛查将导致更早地发现肺 癌（在患者出现症状之前和治疗更可能有效的时候），并将降低死亡率。 11 目前，当患者出现持续性咳嗽、疼痛和体重减轻等症状时，大多数肺癌 被临床诊断；不幸的是，具有这些症状的患者通常是晚期肺癌。肺癌的早 期发现是降低死亡率的重要机会。数据支持使用胸部低剂量 CT (LDCT) 来 筛查选择肺癌高危患者。11-15 不建议将胸部 x 线片用于肺癌筛查。 11,16,17
果的范围。结果局限于以下文章类型：临床试验，2 期；临床试验，3 期；
临床试验，4 期；指南；荟萃分析；随机对照试验；系统综述和验证研究。
在 NCCN 指南更新会议期间，NCCN 肺癌筛查小组选择用于审查的 PubMed 关键文章的数据，以及认为与这些指南相关并由 NCCN 肺癌筛查小组讨论 的其他来源的文章，均已纳入该版本的讨论部分（例如， 提前出版的电子出版物、会议摘要）。如果缺乏高水平证据，建议基于 NCCN 肺癌筛查小组对低水平证据和专家意见的审查。NCCN 指南开发和更 新的完整详情可参见.
NCCN临床实践指南：癌症和化疗诱导的贫血(2014.V2)
Printed by Maria Chen on 9/24/2013 9:50:42 PM. For personal use only. Not approved for distribution. Copyright © 2013 National Comprehensive Cancer Network, Inc., All Rights Reserved.
Clinical Trials: NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged. To find clinical trials online at NCCN Member Institutions, click here: /clinical_trials/physician.aria Chen on 9/24/2013 9:50:42 PM. For personal use only. Not approved for distribution. Copyright © 2013 National Comprehensive Cancer Network, Inc., All Rights Reserved.
NCCN Categories of Evidence and
Consensus: All recommendations are Category 2A unless otherwise specified. See NCCN Categories of Evidence and Consensus.
NCCN指南
NCCN指南
NCCN(Nationa1ComprehensiveCancerNetwork)是美国癌症治疗领域的一个非营利性组织，成立于1995年。
NCCN致力于为临床医生和患者提供关于癌症治疗的最新指南和建议，以促进癌症治疗的发展和优化。
NCCN通过多学科专家委员会的合作，制定了一系列关于各种类型癌症的诊断、治疗和管理的指南。
这些指南是基于最新的临床试验数据、专家的经验和共识，并经过反复审查和修订。
指南的更新频率很高，通常每年都会进行修订。
NCCN指南包括以下方面：
癌症的诊断标准：根据不同类型的癌症，制定相应的诊断标准和检测方法。
癌症的治疗原则：根据癌症的类型、分期和其他因素，制定相应的治疗方案和用药建议，例如手术、放疗、化疗、靶向治疗等。
癌症的辅助治疗：包括早期筛查、预防接种、营养支持、心理治疗等。
癌症的管理和监测：包括转移性癌症的治疗、癌症相关合并症的处理、康复护理等。
NCCN指南对于临床医生和患者来说非常重要，它们提供了最新的、可靠的、科学依据的关于癌症诊断和治疗的信息，帮助医生制定更加精确和有效的治疗方案，同时也为患者提供了更多的参考和指导。
NCCN指南：前列腺癌(中文)
• PSA≤10 个月，已列出首选方案：
术语“去势初治”用于定义进展时未接受 ADT 的患者。NCCN 前列腺癌 Apalutamide（1 类 ）
专家组使用术语“去势初治”，即使患者接受了新辅助、同步或辅助 A
Darolutamide（1 类） Enzalutamide（1 类）
DT 作为放射治疗的一部分，前提是其睾丸功能已恢复。 去势抵抗性前列腺癌 (CRPC) 是尽管血清睾酮去势水平 (< 50 ng/dL)，
• 修改脚注：低风险或良好中等风险疾病男性患者预期寿命≥10 年可以考
虑使用以下基于肿瘤的分子检测：Decipher、Oncotype DX Prostate、Pr
olaris 和 ProMark。患有不利的中高危疾病和预期寿命≥10 年的男性可 以考虑使用基于 Decipher 和 Prolaris 肿瘤的分子检测。
势水平 (< 50 ng/dL)。Scher HI,Halabi S,Tannock I,et al.进展
PROS-12
• 变更：高强度聚焦超声变更为（2B 类）。
• 替换：“ADT（尤其是骨扫描阳性时）或观察结果”，链接为 见去势
性前列腺癌和去势水平睾酮患者临床试验的设计和终点：前列腺癌临
床试验工作组的建议。J Clin Oncol 2008;26:1148-1159.
• 变更：EBRT + 近距离放射治疗±ADT（4 个月）变更为 EBRT
+ 近距离放射治疗±ADT（4-6 mo).
PROS-7 • 预期患者存活，> 5 年或症状改变：EBRT + ADT（1.5–3 年；1 类用
于 ADT) ±多西他赛（1A • 添加以下脚注： 如果在 RP 后发现不良特征，建议使用 Decipher 分子检测来告知
NCCN Guideline_myeloma
NCCN Guidelines Index Multiple Myeloma Table of Contents Discussion George Somlo, MD † ‡ Þ City of Hope Comprehensive Cancer Center Keith Stockerl-Goldstein, MD † x Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine Steven P. Treon, MD, PhD † Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center Guido Tricot, MD, PhD ‡ Huntsman Cancer Institute at the University of Utah Donna Weber, MD † ‡ Þ The University of Texas M. D. Anderson Cancer Center Joachim Yahalom, MD § Memorial Sloan-Kettering Cancer Center Furhan Yunus, MD St. Jude Children’s Research Hospital/University of Tennessee Cancer Institute
Continue
† Medical oncology ‡ Hematology x Bone marrow transplantation ¶ Surgery/Surgical oncology § Radiotherapy/Radiation oncology € Pediatric oncology Þ Internal medicine * Writing conue
nccn指南引用方法
nccn指南引用方法English:When citing the NCCN guidelines, it is important to include the specific version number, the date of publication, and the name of the organization. For example, when referencing the NCCN guidelinesfor prostate cancer, the citation should include the full title of the guidelines, the version number, the publication date, and the National Comprehensive Cancer Network as the author. In-text citations should include the abbreviation "NCCN" followed by the specific version number. For example, "According to the NCCN Clinical Practice Guidelines in Oncology for Prostate Cancer Version , recommended treatment options include..." It is important to use the most recent version of the guidelines when citing information, as the recommendations may change with updated versions. Additionally, always remember to check the NCCN website or official publications for any updates or revisions to the guidelines.中文翻译:在引用NCCN指南时，重要的是包括具体的版本号、出版日期和组织名称。
什么是NCCN指南和CSCO指南
什么是NCCN指南和CSCO指南
我们通常提到的NCCN指南是美国国立综合癌症网络（National Comprehensive Cancer Network ）每年发布的各种恶性肿瘤临床实践指南，得到了全球临床医师的认可和遵循；CSCO指南最重要的特色是立足中国国情，充分考虑华人与西方人种差异、药品遗传学差异、药物可及性、中国社会经济发展情况等方面问题，更便于中国的医生在临床实际中学习和应用。
Y87帝国网站管理系统
指南的形成得益于大量临床研究的成果，通常有效的治疗方案要收录进指南需要经历3~8年的临床研究。
II期临床试验的结果明确显示该种治疗方案有效的时候，才会进入III期临床试验阶段。
因此指南是具有一定时效性的，一些全新的治疗方案并不会第一时间被收录进指南。
Y87帝国网站管理系统
Y87帝国网站管理系统
指南的可及性也是在临床工作中必须要考虑的问题，例如：在国际上的指南中仑伐替尼K药一线推荐用于转移性肾癌，但这种方案目前在国内只有肺癌适应症，这就会导致在临床上合理的“违规用药”问题。
2024肺癌NCCN指南解读英文版
2024肺癌NCCN指南解读英文版Interpreting the 2024 Lung Cancer NCCN GuidelinesIn 2024, the National Comprehensive Cancer Network (NCCN) released updated guidelines for the management of lung cancer. These guidelines provide recommendations for the diagnosis, staging, and treatment of lung cancer based on the latest research and evidence.One key aspect of the 2024 NCCN guidelines is the emphasis on personalized medicine and targeted therapies. The guidelines recommend testing for specific genetic mutations in lung cancer patients to determine the most appropriate treatment options. This approach aims to improve outcomes and reduce side effects by tailoring treatment to the individual patient.Another important update in the 2024 NCCN guidelines is the recommendation for comprehensive staging of lung cancer. Staging is crucial for determining the extent of the disease and guiding treatmentdecisions. The guidelines outline the various imaging and biopsy techniques that should be used to accurately stage lung cancer.Treatment recommendations in the 2024 NCCN guidelines are based on the stage and subtype of lung cancer. Surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy are all potential treatment options depending on the individual patient's situation. The guidelines also highlight the importance of multidisciplinary care and the involvement of a team of specialists in the treatment of lung cancer.In summary, the 2024 Lung Cancer NCCN guidelines provide a comprehensive framework for the management of lung cancer, emphasizing personalized medicine, comprehensive staging, and a multidisciplinary approach to treatment. These guidelines serve as a valuable resource for healthcare providers in delivering optimal care to patients with lung cancer.。
2023骨癌NCCN指南解读英文版
2023骨癌NCCN指南解读英文版Interpreting the 2023 NCCN Guidelines for Bone CancerThe 2023 NCCN Guidelines for Bone Cancer provide valuable insights and recommendations for the diagnosis and treatment of this complex disease. These guidelines offer comprehensive information on the latest advancements in managing bone cancer, emphasizing the importance of early detection and personalized treatment approaches.Bone cancer is a rare but serious condition that requires a multidisciplinary approach for optimal care. The NCCN guidelines outline the different subtypes of bone cancer, their clinical features, and the recommended diagnostic tests for accurate identification. Additionally, the guidelines highlight the various treatment options available, including surgery, radiation therapy, chemotherapy, and targeted therapy, tailored to each patient's specific needs.It is essential for healthcare providers to stay updated on the latest guidelines to ensure the best possible outcomes for patients with bone cancer. By following the recommendations outlined in the NCCN guidelines, healthcare professionals can make informed decisions regarding the management of bone cancer, ultimately improving patient care and quality of life.In conclusion, the 2023 NCCN Guidelines for Bone Cancer serve as a valuable resource for healthcare providers, offering evidence-based recommendations for the diagnosis and treatment of this challenging disease. By adhering to these guidelines, healthcare professionals can provide optimal care for patients with bone cancer, ultimately improving outcomes and quality of life.。
- 1、下载文档前请自行甄别文档内容的完整性，平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益，请联系客服反馈,我们会尽快为您处理(人工客服工作时间：9:00-18:30)。
End User License Agreement
Return to Previous Page
End User License Agreement for NCCN Clinical Practice Guidelines in Oncology
IMPORTANT – READ CAREFULLY: This End User License Agreement (the "Agreement") is a legal agreement between you (either an individual or an entity) and the National Comprehensive Cancer Network, Inc. ("NCCN") covering your use of one (1) CD-ROM version of the NCCN Clinical Practice Guidelines in Oncology, which, together with any updates thereto, are hereinafter referred to collectively as the "Guidelines." BY VIEWING OR OTHERWISE ACCESSING THE DATA CONTAINED ON THIS CD-ROM, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS OF THIS LICENSE AGREEMENT. IF YOU DO NOT AGREE WITH THE TERMS OF THIS LICENSE AGREEMENT, DO NOT VIEW, ACCESS, OR USE THIS CD-ROM AND RETURN THE CD-ROM TO NCCN. 1. Grant of License. NCCN hereby grants to you a nontransferable, non-exclusive, limited license to access and use the Guidelines subject to the terms set forth in this License Agreement. 2. Proprietary Rights. You acknowledge that, as between you and NCCN, NCCN is the owner of all right, title and interest in and to the Guidelines, including, without limitation, all copyrights, trademarks, goodwill, derivative works, and other intellectual property and proprietary rights related thereto. Except for the limited rights expressly enumerated herein, you are not granted any rights relating to copyrights, trade names, trademarks (whether registered or unregistered) or any other rights, franchises or licenses with respect to the Guidelines or NCCN. You hereby agree that you shall not at any time dispute, challenge, or contest, directly or indirectly, NCCN's right, title and interest in and to the Guidelines, or assist or aid others to do so. 3. Restrictions on Use. You may not copy, transfer, reproduce, or create derivative works from, any part of the Guidelines for any
NCCN
®
Practice Guidelines in Oncology – March 2008
s in Oncology
March 2008
V.1.2008
Click here to continue
NCCN
®
Practice Guidelines in Oncology – March 2008
reason. You may make and retain file copies of "Insubstantial Portions" of the Guidelines solely for your internal purposes. "Insubstantial Portions" means a quantity of data from the Guidelines that would not reasonably substitute for a comprehensive copy of the Guidelines and would not prejudice or diminish NCCN's advantage in licensing the Guidelines for commercial gain. Notwithstanding the foregoing, you may include Insubstantial Portions of the Guidelines in materials prepared in the ordinary course of your business for re-distribution to patients in connection with the delivery of your principal services. Any such materials shall cite NCCN as the source of the Guidelines and provide notice of NCCN's copyrights and other proprietary rights, as follows: © National Comprehensive Cancer Network, Inc. 2001-2008. NCCN and NATIONAL COMPREHENSIVE CANCER NETWORK are registered trademarks of National Comprehensive Cancer Network, Inc. You shall provide NCCN with examples of re-distributed materials including any portion of the Guidelines upon NCCN's reasonable request, but shall not be required to provide confidential information to NCCN. You agree to immediately cease any such redistribution on receipt of notice from NCCN that, in NCCN's reasonable judgment, such re-distribution involves more than an Insubstantial Portion of the Guidelines or is otherwise in violation of this Agreement. 4. Limited Warranty; Disclaimers; Limitation of Damages. The Guidelines are a statement of consensus of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. NCCN MAKES NO WARRANTIES CONCERNING THE GUIDELINES OR ANY ELECTRONIC DELIVERY MEDIA SUPPLIED BY NCCN, WHICH ARE PROVIDED "AS IS." NCCN DISCLAIMS
Click Here to Continue
NCCN
®
Practice Guidelines in Oncology – March 2008
End User License Agreement
Return to Previous Page
ALL WARRANTIES, EXPRESS OR IMPLIED INCLUDING, WITHOUT LIMITATION, THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. NCCN DOES NOT WARRANT THE ACCURACY OR COMPLETENESS OF THE GUIDELINES AND DOES NOT WARRANT OR GUARANTEE OR MAKE ANY REPRESENTATION REGARDING THE USE OR THE RESULTS OF THE USE OF THE GUIDELINES. IN NO EVENT SHALL NCCN OR ITS MEMBERS BE LIABLE FOR ANY INCIDENTAL, INDIRECT, SPECIAL, PUNITIVE OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN CONNECTION WITH THE LICENSE GRANTED UNDER THIS AGREEMENT OR USE OF THE GUIDELINES INCLUDING, WITHOUT LIMITATION, LOSS OF LIFE, LOSS OF DATA, LOSS OF INCOME OR PROFIT, OR OTHER LOSSES SUSTAINED AS A RESULT OF INJURY TO ANY PERSON, OR LOSS OR DAMAGE TO PROPERTY, OR CLAIMS OF THIRD PARTIES, EVEN IF NCCN HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. SOME JURISDICTIONS DO NOT ALLOW THE LIMITATION OF IMPLIED WARRANTIES OR LIABILITY FOR INCIDENTAL, INDIRECT, SPECIAL, PUNITIVE OR CONSEQUENTIAL DAMAGES, SO THE ABOVE LIMITATIONS MAY NOT APPLY.